Trividia Health, Inc., the largest U.S. manufacturer of store brand products for people with diabetes, and Mellitus Health, Inc., a leading innovator of software for diabetes care professionals who manage insulin therapy, have partnered to develop solutions to help improve diabetes care through pharmacies and pharmacy-based clinics. Read More »

Sentry Data Systems, Inc., a leader in pharmacy procurement and utilization management, 340B compliance and advanced healthcare analytics solutions, today announced the addition of Claims Manager Plus, an innovative new solution that helps hospitals adhere to payer reporting requirements — minimizing payer denials and accelerating payment for 340B covered entities' Medicaid pharmacy claims. Read More »

Florida-based SMP Pharmacy Solutions announces strategic acquisition of Northridge Plaza Pharmacy to serve growing demand in California fertility market Read More »

Study Evaluated Efficacy and Safety of ABP 798 Compared to Rituxan in Patients With Non-Hodgkin's Lymphoma Read More »

Further Expanding Its Vast Array of Services and Solutions for Community Pharmacies, TDS Offers a Seamless, Scalable Delivery Solution for Computer-Rx and Rx30 Users Read More »

Adding drug collection units in 53 pharmacy store locations across the state to increase community access to safe disposal of unwanted medications Read More »

All 140 CVS Pharmacy locations in Minnesota area now using time-delay safe technology Read More »

Amgen (NASDAQ: AMGN) today announced that it is making Repatha® (evolocumab), an innovative biologic medicine for people with high cholesterol who are at risk for heart attacks and strokes, available at a reduced list price of $5,850 per year. Read More »

Researchers from the University of Central Florida recently received a $400,000 grant from the Juvenile Diabetes Research Foundation, which they will use to create a tube that resists infection and encapsulation and is inserted under the skin for the delivery of insulin via a pump. Read More »

Amgen (NASDAQ:AMGN) today announced that the results of two open-label extension (OLE) studies of Aimovig™ (erenumab-aooe) in patients with chronic and episodic migraine, respectively, will be presented at the 60th Annual Scientific Meeting of the American Headache Society (AHS) in San Francisco. Read More »

Amgen (NASDAQ:AMGN) today announced new data that show Repatha® (evolocumab) significantly reduced low-density lipoprotein cholesterol (LDL-C) and non-high density lipoprotein cholesterol (non-HDL-C) in patients with Type 2 diabetes and hypercholesterolemia or mixed dyslipidemia, taking the maximum tolerated dose of moderate/high-intensity statin therapy. Read More »

Amgen (NASDAQ:AMGN) today announced results from the Phase 3 A.R.R.O.W. trial of a once-weekly KYPROLIS® (carfilzomib) dosing regimen in patients with relapsed and refractory multiple myeloma. Read More »

Boehringer-Ingelheim issued the following announcement on May 21.Breckenridge Pharmaceutical, Inc. announced today the supplemental approval for the 40mg strength of Duloxetine Delayed-Release Capsules. Read More »

Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved the use of Prolia® (denosumab) for the treatment of glucocorticoid-induced osteoporosis (GIOP) in men and women at high risk of fracture, defined as a history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy. Read More »

Amgen (NASDAQ: AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved Aimovig™ (erenumab-aooe) for the preventive treatment of migraine in adults. Read More »

Amgen announced that it will report its first quarter 2018 financial results on Tuesday, April 24, 2018, after the close of the U.S. financial markets. Read More »

Just announced full results from the Phase 3b LIBERTY trial of Aimovig™ (erenumab) in episodic migraine patients who had previously failed two to four preventive treatments, due to lack of efficacy or to intolerable side effects. Read More »

Amgen (NASDAQ:AMGN) today announced plans to build a new state-of-the-art next-generation biomanufacturing plant at its campus in West Greenwich, R.I. The new plant, the first of its kind in the United States (U.S.), will employ Amgen's proven next-generation biomanufacturing capabilities and manufacture products for the U.S. and global markets. Read More »

Amgen (NASDAQ:AMGN) today announced that new pre-clinical data for several of its novel investigational oncology candidates will be presented at the American Association for Cancer Research (AACR) Annual Meeting in Chicago, April 14-18, 2018. Read More »

Applied Genetic Technologies Corporation (NASDAQ:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced the election of Sue Washer, President and Chief Executive Officer, to the Biotechnology Innovation Organization (BIO)'s Board of Directors. Read More »